Perjeta (Pertuzumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Perjeta (Pertuzumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increased adoption of oncology treatments, rising demand for antibody-drug conjugates (ADCs), the need for targeted and less toxic therapies, increased inorganic growth, and the growing demand for personalized and targeted medicine.

Market growth during the forecast period is driven by the rising incidence of breast cancer, growing interest in ADCs for hematologic malignancies, increasing cancer rates, unmet medical needs, and rising pharmaceutical R&D in cancer immunotherapy. Key trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovations in drug formulations, advances in cancer immunotherapy research, and the growing prominence of combination therapies.

The rising incidence of breast cancer is expected to drive the growth of the perjeta (pertuzumab) market. Breast cancer is a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The increase in breast cancer cases is attributed to factors like lifestyle changes, such as higher obesity rates and sedentary habits, along with improvements in early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy for enhanced treatment outcomes. For example, in October 2023, the Ray of Light Wales, a UK-based charity, reported that the number of people living after a breast cancer diagnosis in the UK is projected to double from 600,000 in 2023 to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the perjeta market.

A key trend in the perjeta (pertuzumab) market is the focus on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve the combination of two or more drugs in a single subcutaneous injection to treat a specific condition. In November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment combines pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing time compared to traditional intravenous infusions. Phesgo is the first subcutaneous option for HER2-positive colorectal cancer, marking a major advancement in treatment delivery.

In June 2024, Zydus Pharmaceuticals, an India-based company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve the affordability, availability, and patient outcomes by leveraging their combined distribution efforts. Dr. Reddy’s Laboratories, a key player in the Indian pharmaceutical sector, offers pertuzumab biosimilars, making this partnership a significant step toward increasing the accessibility of this treatment in the region.

Key player operating in the perjeta (pertuzumab) market is Roche Holding AG.

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in perjeta (pertuzumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the perjeta (pertuzumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Perjeta (pertuzumab) is a targeted therapy used in the treatment of specific types of breast cancer. It is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2), a protein that accelerates the growth of cancer cells in HER2-positive breast cancer.

The primary types of perjeta (pertuzumab) are human source and animal source. While Perjeta is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, animal-derived components may be used in the production process. It includes products like monoclonal antibodies and biologic drugs, with indications for conditions such as early-stage and metastatic breast cancer. Perjeta is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The perjeta (pertuzumab) market research report is one of a series of new reports that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.